You are here

Juno jumps on cancer therapy wave

But the journey to commercialising the bespoke medication remains daunting

BT_20141222_CANCER22_1422728.jpg
Juno shot up to US$35 on Friday after its shares were priced at US$24 on Thursday to raise more than US$200 million.

Minneapolis

IT'S a cancer therapy straight out of Greek mythology, bespoke medicine with astonishing results in the smallest and sickest of patients.

The treatment, called a chimeric antigen receptor, or CAR for short, has captured the attention of the biggest drug companies and

sentifi.com

Market voices on:

Powered by GET.comGetCom